Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Shares Issued (2016 - 2025)

Ani Pharmaceuticals' Shares Issued history spans 16 years, with the latest figure at $38000.0 for Q4 2025.

  • For Q4 2025, Shares Issued rose 100.79% year-over-year to $38000.0; the TTM value through Dec 2025 reached $13.6 million, changed N/A, while the annual FY2025 figure was $13.6 million, N/A changed from the prior year.
  • Shares Issued for Q4 2025 was $38000.0 at Ani Pharmaceuticals, down from $9.8 million in the prior quarter.
  • Across five years, Shares Issued topped out at $79.1 million in Q3 2023 and bottomed at -$4.8 million in Q4 2024.
  • The 5-year median for Shares Issued is $1.0 million (2024), against an average of $5.7 million.
  • The largest annual shift saw Shares Issued tumbled 100.89% in 2022 before it surged 43066.67% in 2023.
  • A 5-year view of Shares Issued shows it stood at $1.7 million in 2021, then crashed by 55.68% to $768000.0 in 2022, then surged by 10200.65% to $79.1 million in 2023, then plummeted by 106.05% to -$4.8 million in 2024, then skyrocketed by 100.79% to $38000.0 in 2025.
  • Per Business Quant, the three most recent readings for ANIP's Shares Issued are $38000.0 (Q4 2025), $9.8 million (Q3 2025), and $1.2 million (Q2 2025).